Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20259075 | 0.88 | DGAT2 (0.43) | DGAT2CA1CA2CA12CA9 | |
| SCHEMBL20239318 | 0.88 | LMNA (0.45) | DGAT2LMNATSHRNPSR1CA1 | |
| SCHEMBL18249768 | 0.86 | DGAT2 (0.44) | DGAT2LMNACA1CA2CA12 | |
| SCHEMBL20259162 | 0.86 | DGAT2 (0.42) | DGAT2CA1CA2CA12CA9 | |
| SCHEMBL20259248 | 0.85 | DGAT2 (0.41) | DGAT2CA1CA2CA12CA9 | |
| SCHEMBL20239235 | 0.73 | DGAT2 (0.44) | DGAT2LMNANPSR1MEN1KMT2A | |
| SCHEMBL20239312 | 0.73 | DGAT2 (0.47) | DGAT2LMNACA1CA2CA9 | |
| SCHEMBL20239264 | 0.73 | DGAT2 (0.45) | DGAT2LMNATSHRNPSR1MAPT | |
| SCHEMBL20239187 | 0.73 | LMNA (0.41) | DGAT2LMNATSHRNPSR1CA1 | |
| SCHEMBL20239327 | 0.72 | DGAT2 (0.44) | DGAT2LMNATSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635975-B | DGAT2 inhibitors | 伊莱利利公司 | 2020-07-24 | — | — | CN | disclosed |
| EP-3298001-B1 | DGAT2 INHIBITORS | LILLY CO ELI (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10053429-B2 | DGAT2 inhibitors | ELI LILLY AND COMPANY (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | DGAT2 1/4885LMNA 2022/4885TSHR 777/4885 |
| US-10053429-B2 | DGAT2 inhibitors | DGAT2, DGAT1, LCAT | DGAT2 1/4885LMNA 1722/4885TSHR 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.